Literature DB >> 27990354

Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.

Jin Woo Kwon1, Jin A Choi1, Eun Young Shin2, Tae Yoon La1, Dong Hyun Jee1, Yeon Woong Chung1, Yang Kyung Cho1.   

Abstract

AIM: To evaluate whether trapping vascular endothelial growth factor A (VEGF-A) would suppress angiogenesis and inflammation in dry eye corneas in a murine corneal suture model.
METHODS: We established two groups of animals, one with non-dry eyes and the other with induced dry eyes. In both groups, a corneal suture model was used to induce inflammation and neovascularization. Each of two groups was again divided into three subgroups according to the treatment; subgroup I (aflibercept), subgroup II (dexamethasone) and subgroup III (phosphate buffered saline, PBS). Corneas were harvested and immunohistochemical staining was performed to compare the extents of neovascularization and CD11b+ cell infiltration. Real-time polymerase chain reaction was performed to quantify the expression of inflammatory cytokines and VEGF-A in the corneas.
RESULTS: Trapping VEGF-A with aflibercept resulted in significantly decreased angiogenesis and inflammation compared with the dexamethasone and PBS treatments in the dry eye corneas (all P<0.05), but with no such effects in non-dry eyes. The anti-inflammatory and anti-angiogenic effects of VEGF-A trapping were stronger than those of dexamethasone in both dry eye and non-dry eye corneas (all P<0.05). The levels of RNA expression of VEGF-A, TNF-alpha, and IL-6 in the aflibercept subgroup were significantly decreased compared with those in the PBS subgroup in the dry eye group.
CONCLUSION: Compared with non-dry eye corneas, dry eye corneas have greater amounts of inflammation and neovascularization and also have a more robust response to anti-inflammatory and anti-angiogenic agents after ocular surface surgery. Trapping VEGF-A is effective in decreasing both angiogenesis and inflammation in dry eye corneas after ocular surface surgery.

Entities:  

Keywords:  aflibercept; dexamethasone; dry eye; inflammation; neovascularization

Year:  2016        PMID: 27990354      PMCID: PMC5145079          DOI: 10.18240/ijo.2016.11.02

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  42 in total

Review 1.  The core mechanism of dry eye disease is inflammation.

Authors:  Yi Wei; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2014-07       Impact factor: 2.018

Review 2.  Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.

Authors:  Stefano Barabino; Yihe Chen; Sunil Chauhan; Reza Dana
Journal:  Prog Retin Eye Res       Date:  2012-03-08       Impact factor: 21.198

3.  Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye.

Authors:  Hyun Soo Lee; Sunil K Chauhan; Andre Okanobo; Nambi Nallasamy; Reza Dana
Journal:  Cornea       Date:  2011-12       Impact factor: 2.651

4.  Dry eye predisposes to corneal neovascularization and lymphangiogenesis after corneal injury in a murine model.

Authors:  Yang Kyung Cho; Bonnie Archer; Balamurali K Ambati
Journal:  Cornea       Date:  2014-06       Impact factor: 2.651

Review 5.  Rethinking dry eye disease: a perspective on clinical implications.

Authors:  Anthony J Bron; Alan Tomlinson; Gary N Foulks; Jay S Pepose; Christophe Baudouin; Gerd Geerling; Kelly K Nichols; Michael A Lemp
Journal:  Ocul Surf       Date:  2014-02-13       Impact factor: 5.033

6.  HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease.

Authors:  Seth P Epstein; Neha Gadaria-Rathod; Yi Wei; Maureen G Maguire; Penny A Asbell
Journal:  Exp Eye Res       Date:  2013-04-06       Impact factor: 3.467

Review 7.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

8.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

9.  Dry eye after cataract surgery and associated intraoperative risk factors.

Authors:  Yang Kyeung Cho; Man Soo Kim
Journal:  Korean J Ophthalmol       Date:  2009-06-09

10.  Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.

Authors:  Xiaodan Jiang; Huibin Lv; Weiqiang Qiu; Ziyuan Liu; Xuemin Li; Wei Wang
Journal:  Drug Des Devel Ther       Date:  2015-06-12       Impact factor: 4.162

View more
  3 in total

1.  Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity.

Authors:  Xiaodan Jiang; Yuexin Wang; Huibin Lv; Yan Liu; Mingzhou Zhang; Xuemin Li
Journal:  Drug Des Devel Ther       Date:  2018-05-16       Impact factor: 4.162

Review 2.  Experimental Models, Induction Protocols, and Measured Parameters in Dry Eye Disease: Focusing on Practical Implications for Experimental Research.

Authors:  Md Mahbubur Rahman; Dong Hyun Kim; Chul-Kyu Park; Yong Ho Kim
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

3.  Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1α.

Authors:  Ying-Cong Fu; Zhi-Ming Xin
Journal:  Biosci Rep       Date:  2019-01-30       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.